Dipeptidyl peptidase-4 inhibitor linagliptin reduces inflammatory response, ameliorates tissue edema formation, and improves survival in severe sepsis.
Ampersand Biosciences was cited in the article titled, “Dipeptidyl peptidase-4 inhibitor linagliptin reduces inflammatory response, ameliorates tissue edema formation, and improves survival in severe sepsis” for measuring cytokine and chemokine content in plasma samples that could measure drug exposure in mice of linagliptin, a DDP-4 (dipeptidyl peptidase-4) ihibitor.
Species: Mouse
Focus: Sepsis induced pro-inflammatory cytokine and chemokine production.